NCT04244656 - A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

CTX120

CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.

Trial Locations (10)

2050

Royal Prince Alfred Hospital, Sydney

3000

Peter MacCallum Cancer Centre, Melbourne

19104

University of Pennsylvania, Philadelphia

31008

Universidad de Navarra, Pamplona

37007

Hospital Universitario de Salamanca, Salamanca

37203

Sarah Cannon Research Institute, Nashville

60637

University of Chicago, Chicago

97239

Oregon Health and Science University, Portland

M5G 1X6

University Health Network, Princess Margaret Cancer Centre, Toronto

08916

Institut Catala d'Oncologia Hospital Germans Trias i Pujol, Badalona